Findings

What do systematic reviews say?

166 questions · 178 findings · 15 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 52 · 29.2%GRADE not reported 1 · 0.6%Very low 44 · 24.7%Low 56 · 31.5%Moderate 24 · 13.5%High 1 · 0.6%

Oestrogen therapy alone vs surgery

Participant adherence to intervention · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs surgery

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs surgery

Major adverse events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Objective improvement or cure of POP symptoms · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Generic quality of life measures · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Participant adherence to intervention · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Major adverse events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs pelvic floor muscle training (PFMT)

Subjective improvement or cure of POP symptoms · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs pelvic floor muscle training (PFMT)

Improvement or cure of associated sexual symptoms · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen

Symptoms score: Premenstrual Daily Questionnaire (PDQ) Scale from 0 to 30, with a higher score indicating a worse outcome over 8 months · women with PMS

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
Very low

Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen

Withdrawals due to adverse events · women with PMS

It is very uncertain whether dose comparison: oestrogen 100 µg patch changes adverse events ‐ withdrawal rates over 8 months' compared with 200 µg patch plus progestogen (very low certainty).

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
RR 0.7 [0.34, 1.46]
1 study · 107 participants
Very low

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

Symptom scores over 2 to 4 menstrual cycles1 · women with PMS

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 158 participants
Very low

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

Withdrawals due to adverse events · women with PMS

It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
RR 0.64 [0.26, 1.58]
3 studies · 196 participants
Very low

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

Specific adverse events · women with PMS

It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
206 participants
Very low

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Uterine volume (cm³) · girls with Turner syndrome who were treated with prepubertal growth hormone

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Endometrial thickness (mm) · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Endometrial histology · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Uterine perfusion · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Reproductive outcomes · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found